Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic
Aishwarya Ravindran(Mayo Clinic in Arizona), Ronald S. Go(Mayo Clinic), Shaji Kumar(Mayo Clinic), Matthew T. Drake(Hospital for Special Surgery), Taxiarchis Kourelis(Mayo Clinic in Arizona), Eli Muchtar(Mayo Clinic), Kandace A. Lackore(Mayo Clinic), Amy E. Glasgow(Mayo Clinic in Arizona), Nelson Leung(WinnMed), Miriam Hobbs, Robert A. Kyle(Mayo Clinic)
Cited by 16
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Prevalence of Monoclonal Gammopathy of Undetermined Significance
|New England Journal of Medicine|2006|1.4k